Il tuo browser è obsoleto
Con un browser aggiornato, l'esperienza sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.
Si, sono un operatore sanitario
I contenuti presenti nella pagina che segue contengono informazioni rivolte esclusivamente agli OPERATORI SANITARI, in quanto si riferiscono a prodotti rientranti nella categoria dei dispositivi medici che richiedono l’impiego o l’intervento da parte di professionisti del settore medico-sanitario.
The Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 35 mm in native coronary arteries with reference vessel diameters of 2.0 mm to 5.0 mm. In addition, the Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is indicated for treating de novo chronic total occlusions.
The Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is contraindicated for use in: ● Patients with a known hypersensitivity or allergies to aspirin, heparin, bivalirudin, clopidogrel, prasugrel, ticagrelor, ticlopidine, drugs such as zotarolimus, tacrolimus, sirolimus, everolimus, or similar drugs or any other analogue or derivative ● Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium, and molybdenum) or platinum-iridium alloy ● Patients with a known hypersensitivity to the BioLinx® polymer or its individual components
Coronary artery stenting is contraindicated for use in: ● Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated ● Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system
● Please ensure that the inner package has not been opened or damaged as this would indicate the sterile barrier has been breached. ● The use of this product carries the same risks associated with coronary artery stent implantation procedures, which include subacute and late vessel thrombosis, vascular complications, and/or bleeding events. ● This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.
● Only physicians who have received adequate training should perform implantation of the stent. ● Subsequent stent restenosis or occlusion may require repeat catheter-based treatments (including balloon dilatation) of the arterial segment containing the stent. The long-term outcome following repeat catheter-based treatments of previously implanted stents is not well characterized. ● The risks and benefits of the stent implantation should be assessed for patients with a history of severe reaction to contrast agents. ● Do not expose or wipe the product with organic solvents such as alcohol. ● The use of a drug-eluting stent (DES) outside of the labeled indications, including use in patients with more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death. ● Care should be taken to control the position of the guide catheter tip during stent delivery, stent deployment, and balloon withdrawal. Before withdrawing the stent delivery system, confirm complete balloon deflation using fluoroscopy to avoid arterial damage caused by guiding catheter movement into the vessel. ● Stent thrombosis is a low-frequency event that is frequently associated with myocardial infarction (MI) or death. Data from the RESOLUTE clinical trials have been prospectively evaluated and adjudicated using the definition developed by the Academic Research Consortium (ARC).
The safety and effectiveness of the Resolute Onyx™ stent have not yet been established in the following patient populations: ● Patients with target lesions that were treated with prior brachytherapy or the use of brachytherapy to treat in-stent restenosis of a Resolute Onyx™ stent ● Women who are pregnant or lactating ● Men intending to father children ● Pediatric patients ● Patients with coronary artery reference vessel diameters of <2.0 mm or >5.0 mm ● Patients with evidence of an acute ST-elevation MI within 72 hours of intended stent implantation ● Patients with vessel thrombus at the lesion site ● Patients with lesions located in a saphenous vein graft, in the left main coronary artery, ostial lesions, or bifurcation lesions ● Patients with diffuse disease or poor flow distal to identified lesions ● Patients with three-vessel disease
The safety and effectiveness of the Resolute Onyx™ stent have not been established in the cerebral, carotid, or peripheral vasculature.
Other risks associated with using this device are those associated with percutaneous coronary diagnostic (including angiography and IVUS) and treatment procedures. These risks (in alphabetical order) may include but are not limited to: ● Abrupt vessel closure ● Access site pain, hematoma, or hemorrhage ● Allergic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer coating) ● Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF) ● Arrhythmias, including ventricular fibrillation ● Balloon rupture ● Bleeding ● Cardiac tamponade ● Coronary artery occlusion, perforation, rupture, or dissection ● Coronary artery spasm ● Death ● Embolism (air, tissue, device, or thrombus) ● Emergency surgery: peripheral vascular or coronary bypass ● Failure to deliver the stent ● Hemorrhage requiring transfusion ● Hypotension/hypertension ● Incomplete stent apposition ● Infection or fever ● MI ● Pericarditis ● Peripheral ischemia/peripheral nerve injury ● Renal failure ● Restenosis of the stented artery ● Shock/pulmonary edema ● Stable or unstable angina ● Stent deformation, collapse, or fracture ● Stent migration or embolization ● Stent misplacement ● Stroke/transient ischemic attack ● Thrombosis (acute, subacute, or late)
Patients’ exposure to zotarolimus is directly related to the total amount of stent length implanted. The actual side effects/complications that may be associated with the use of zotarolimus are not fully known. The adverse events that have been associated with the intravenous injection of zotarolimus in humans include but are not limited to: ● Anemia ● Diarrhea ● Dry skin ● Headache ● Hematuria ● Infection ● Injection site reaction ● Pain (abdominal, arthralgia, injection site) ● Rash
Please reference appropriate product Instructions for Use for more information regarding indications, warnings, precautions, and potential adverse events.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
For further information, please call and/or consult Medtronic at the toll-free numbers or websites listed.
© 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.
Medtronic Italia S.p.A. Società soggetta ad attività di direzione e coordinamento da parte di Medtronic Inc.
Cap. soc. € 1.200.000,00 - Registro Imprese N. 281327 Tribunale Milano - R.E.A. N. 1275682 - Cod. Fisc./P.IVA 09238800156
Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano